Cargando…
microRNA based prognostic biomarkers in pancreatic Cancer
Despite tremendous research efforts focused on diagnosis and treatment, pancreatic ductal adenocarcinoma remains the third leading cause of cancer-related death in the United States, with a 5-year overall survival rate of less than 5%. Although resistance is rather complex, emerging evidence has dem...
Autores principales: | Guo, Shixiang, Fesler, Andrew, Wang, Huaizhi, Ju, Jingfang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5963153/ https://www.ncbi.nlm.nih.gov/pubmed/29942514 http://dx.doi.org/10.1186/s40364-018-0131-1 |
Ejemplares similares
-
Development of microRNA-based therapy for pancreatic cancer
por: Fesler, Andrew, et al.
Publicado: (2019) -
Expression analysis of microRNA as prognostic biomarkers in colorectal cancer
por: Yang, Jie, et al.
Publicado: (2016) -
Implications of Circadian Rhythm Regulation by microRNAs in Colorectal Cancer
por: Wu, Song, et al.
Publicado: (2016) -
Functional Significance and Therapeutic Potential of miR-15a Mimic in Pancreatic Ductal Adenocarcinoma
por: Guo, Shixiang, et al.
Publicado: (2019) -
miR-129 as a novel therapeutic target and biomarker in gastrointestinal cancer
por: Fesler, Andrew, et al.
Publicado: (2014)